SANUWAVE, Inc.

SANUWAVE, Inc. is a medical technology company focused on innovative solutions for advanced wound care through patented devices that enhance healing processes for chronic and acute wounds. Founded in Alpharetta, US, SANUWAVE Health, Inc. specializes in developing advanced technologies for wound care, including its flagship products, the UltraMIST® System and the dermaPACE® System.

The company has maintained a consistent focus on enhancing wound management without notable pivots in its business strategy. Morgan Frank serves as the CEO, bringing a wealth of experience in medical technology. The company has successfully raised funds through multiple rounds to support its operations. SANUWAVE Health, Inc.

specializes in advanced wound care technologies, primarily through its flagship products, the UltraMIST® System and the dermaPACE® System. The UltraMIST® System utilizes non-invasive ultrasonic technology to enhance the healing process of chronic and acute wounds by promoting tissue regeneration and reducing healing time. Similarly, the dermaPACE® System employs patented acoustic pressure wave technology to stimulate healing in soft tissue injuries, particularly for conditions like diabetic foot ulcers and pressure sores. These products are designed for use in clinical settings, such as hospitals and outpatient care facilities, catering to a diverse clientele that includes healthcare providers and practitioners focused on wound management.

SANUWAVE products have a global reach, with significant market presence in North America, Europe, and parts of Asia, addressing critical medical needs across various geographical regions. SANUWAVE Health operates on a revenue model predominantly driven by direct sales of its clinical products, as well as potential partnerships with healthcare institutions and distributors. The company's revenue streams are bolstered through the sale of its trademarked systems, with a focus on providing innovative solutions for wound care. In this structure, healthcare providers typically purchase the UltraMIST® and dermaPACE® Systems directly for use in their facilities, creating a direct B2B transaction environment.

Additionally, the company may engage in collaborative agreements with medical institutions or distributors to enhance product reach and accessibility. Specific pricing details for the products are integral to this model, as they establish a framework for transactions and inform healthcare providers of the financial commitments involved in acquiring the technology.